170 results
8-K
EX-99.1
EGRX
Eagle Pharmaceuticals Inc
22 May 24
Eagle Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq
9:08am
with research and development, clinical, manufacturing and commercial expertise. Eagle is committed to developing innovative medicines that result
8-K
EX-99.1
EGRX
Eagle Pharmaceuticals Inc
12 Apr 24
Eagle Pharmaceuticals Announces Receipt of Notification of Deficiency from Nasdaq Regarding Requirement to Timely File Annual Report on Forward-Looking Statements Disclaimer
4:16pm
listing on Nasdaq.
About Eagle Pharmaceuticals, Inc.
Eagle is a fully integrated pharmaceutical company with research and development, clinical
8-K
EX-10.1
EGRX
Eagle Pharmaceuticals Inc
8 Mar 24
Departure of Directors or Certain Officers
4:49pm
, studies, analyses, proposals, agreements, drafts, financial and operational information, research and development information, sales and marketing
8-K
EX-99.1
EGRX
Eagle Pharmaceuticals Inc
18 Jan 24
Eagle Pharmaceuticals Provides Update on Bendamustine Intellectual Property Portfolio
6:56am
is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial expertise. Eagle is committed
8-K
EX-99.1
EGRX
Eagle Pharmaceuticals Inc
6 Dec 23
Regulation FD Disclosure
4:26pm
, Inc.
Eagle is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial expertise. Eagle
8-K
EX-99.1
2njcxt0
29 Nov 23
Eagle Pharmaceuticals Announces Receipt of Notification of Deficiency from Nasdaq Regarding Requirement to Timely File Quarterly Report on Form 10-Q
7:39am
8-K
EX-99.1
ki4meu4xzoj
29 Nov 23
Eagle Pharmaceuticals Announces Management Change
7:36am
8-K
EX-10.1
qe9l4i7hjf0ihg0row
29 Nov 23
Eagle Pharmaceuticals Announces Management Change
7:36am
8-K
EX-99.1
0cj4dvc1wuw7so wb
9 Nov 23
Eagle Delays Third Quarter 2023 Results and Conference Call
7:57am
8-K
EX-99.1
gvcb ezqq1
24 Oct 23
Regulation FD Disclosure
8:49am
8-K
EX-99.1
anqlwkbfro2l4tk
23 Oct 23
Eagle Pharmaceuticals Granted Unique J-Code and Pass-Through Status for BARHEMSYS® from CMS
7:10am
8-K
EX-99.1
6dn2w g5al40v
27 Sep 23
Regulation FD Disclosure
7:00am
8-K
EX-99.1
uuezn a7vts
7 Sep 23
Regulation FD Disclosure
7:20am
8-K
EX-99.1
o5p5wm1s4nxld
29 Aug 23
Eagle Pharmaceuticals Announces Positive Type C Meeting with FDA for EA-114, an Estrogen Receptor Antagonist Used in the Treatment of
6:55am
8-K
EX-99.1
osrasc
17 Aug 23
Regulation FD Disclosure
6:59am
8-K
EX-99.1
ddx8ntnihsm
8 Aug 23
Eagle Pharmaceuticals Reports Second Quarter 2023 Results
7:06am
8-K
EX-99.1
rnlr5k08l2 0tec8e48
31 Jul 23
Regulation FD Disclosure
6:59am
8-K
EX-99.1
lqda8g11xbf3ube62ok
24 Jul 23
Despite the availability of antibiotics, the death rate from pneumonia in the U.S. has seen little improvement in the past half century1
7:00am